The post reports that a main clinical study for Amgen's drug Tavneos was retracted from the New England Journal of Medicine, potentially jeopardizing the drug's continued sales.
bloomberg-industries06/30, 02:00 AM
Related assets
Coming up for AMGN
Explore next
Latest AMGN news
Finnhub09/08, 09:50 PM
Jin1008/21, 10:49 PM
FirstSquawk08/05, 03:07 AM
Amgen raised its full-year adjusted EPS guidance to $22.30-$23.50 from the prior $21.70-$23.10.